JP7177076B2 - チロシン原栄養性 - Google Patents

チロシン原栄養性 Download PDF

Info

Publication number
JP7177076B2
JP7177076B2 JP2019549562A JP2019549562A JP7177076B2 JP 7177076 B2 JP7177076 B2 JP 7177076B2 JP 2019549562 A JP2019549562 A JP 2019549562A JP 2019549562 A JP2019549562 A JP 2019549562A JP 7177076 B2 JP7177076 B2 JP 7177076B2
Authority
JP
Japan
Prior art keywords
nucleic acid
interest
sequence
host cell
acid construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019549562A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020509763A (ja
JP2020509763A5 (https=
Inventor
ウォルター ヒラー グレゴリー
ジョセフ ミッチェル ジェフリー
チャンドラ ムルクトラ バヌー
マリー ペグマン パメラ
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2020509763A publication Critical patent/JP2020509763A/ja
Publication of JP2020509763A5 publication Critical patent/JP2020509763A5/ja
Application granted granted Critical
Publication of JP7177076B2 publication Critical patent/JP7177076B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16001—Phenylalanine 4-monooxygenase (1.14.16.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01096—4a-Hydroxytetrahydrobiopterin dehydratase (4.2.1.96)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2019549562A 2017-03-16 2018-03-09 チロシン原栄養性 Active JP7177076B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762472225P 2017-03-16 2017-03-16
US62/472,225 2017-03-16
US201862628018P 2018-02-08 2018-02-08
US62/628,018 2018-02-08
PCT/IB2018/051572 WO2018167621A1 (en) 2017-03-16 2018-03-09 Tyrosine prototrophy

Publications (3)

Publication Number Publication Date
JP2020509763A JP2020509763A (ja) 2020-04-02
JP2020509763A5 JP2020509763A5 (https=) 2021-04-08
JP7177076B2 true JP7177076B2 (ja) 2022-11-22

Family

ID=61802237

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019549562A Active JP7177076B2 (ja) 2017-03-16 2018-03-09 チロシン原栄養性

Country Status (5)

Country Link
US (1) US20200056190A1 (https=)
EP (1) EP3596206A1 (https=)
JP (1) JP7177076B2 (https=)
CA (1) CA3056182A1 (https=)
WO (1) WO2018167621A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7001585B2 (ja) * 2015-09-23 2022-02-04 ファイザー・インク 細胞および細胞培養の方法
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
US20190256867A1 (en) 2018-02-01 2019-08-22 Homology Medicines, Inc. Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
WO2020084034A1 (en) 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
EP3938515A4 (en) * 2019-03-13 2022-12-28 Generation Bio Co. NON-VIRAL DNA VECTORS AND THEIR USES FOR EXPRESSING PHENYLALANINE HYDROXYLASE (PAH) THERAPEUTIC AGENTS
US20220403398A1 (en) * 2019-11-14 2022-12-22 Lonza Ltd Methods of cell selection
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
EP4158005A1 (en) * 2020-06-01 2023-04-05 ModernaTX, Inc. Phenylalanine hydroxylase variants and uses thereof
US20240124850A1 (en) 2021-03-03 2024-04-18 Shape Therapeutics Inc. Auxotrophic Cells for Virus Production and Compositions and Methods of Making

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068822A2 (en) 2000-03-14 2001-09-20 Nilab Aps Method of treating phenylketonuria and means therefor
WO2012027533A1 (en) 2010-08-25 2012-03-01 Gt Life Sciences, Inc. Selectable markers and related methods
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
AU2353384A (en) * 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) * 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
CA2489769A1 (en) 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
AU648261B2 (en) 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
PT695169E (pt) 1993-04-22 2003-04-30 Skyepharma Inc Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
DK0814154T3 (da) 1993-09-15 2009-08-31 Novartis Vaccines & Diagnostic Rekombinante alfavirusvektorer
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
AU686277B2 (en) 1993-11-16 1998-02-05 Pacira Pharmaceuticals, Inc. Vesicles with controlled release of actives
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
WO1997042338A1 (en) 1996-05-06 1997-11-13 Chiron Corporation Crossless retroviral vectors
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
AU2010247938B2 (en) * 2009-05-11 2016-02-18 Pelican Technology Holdings, Inc. Production of recombinant proteins utilizing non-antibiotic selection methods and the incorporation of non-natural amino acids therein
EP2714936B1 (en) * 2011-06-01 2018-12-12 Precision Biosciences, Inc. Methods and products for producing engineered mammalian cell lines with amplified transgenes
EP2711428A1 (en) 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
US20160230200A1 (en) * 2013-09-05 2016-08-11 Danmarks Tekniske Universitet Microorganisms for efficient production of melatonin and related compounds
HRP20200529T1 (hr) * 2014-06-06 2020-09-04 Regeneron Pharmaceuticals, Inc. Postupci i pripravci za modificiranje ciljnog lokusa
JP7001585B2 (ja) * 2015-09-23 2022-02-04 ファイザー・インク 細胞および細胞培養の方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068822A2 (en) 2000-03-14 2001-09-20 Nilab Aps Method of treating phenylketonuria and means therefor
WO2012027533A1 (en) 2010-08-25 2012-03-01 Gt Life Sciences, Inc. Selectable markers and related methods
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Ledley FD et al.，Selection for phenylalanine hydroxylase activity in cells transformed with recombinant retroviruses.，Somatic Cell and Molecular Genetics，1987年，Vol. 13（2），pp. 145 -154
Nehlsen, K. et al.，Recombinant protein expression by targeting pre-selected chromosomal loci，BMC Biotechnol.，2009年，Vol. 9:100，pp. 1-12
P16331 (PH4H_MOUSE) ，UniProtKB[online] ，2016年10月10日，URL: https://web.archive.org/web/20161010222707/https://www.uniprot.org/uniprot/P16331#subcellular_location，[retrieved on 12.23.2021]
Song, J. et al.，PhhB, a Pseudomonas aeruginosa homolog of mammalian pterin 4a-carbinolamine dehydratase/DCoH, does not regulate expression of phenylalanine hydroxylase at the transcriptional level，J. Bacteriol.，1999年，Vol. 181(9)，pp. 2789-2796
Staudigl, M. et al.，The interplay between genotype, metabolic state and cofactor treatment governs phenylalanine hydroxylase function and drug response.，Hum. Mol. Genet.，2011年，Vol. 20(13)，pp. 2628-2641

Also Published As

Publication number Publication date
EP3596206A1 (en) 2020-01-22
WO2018167621A1 (en) 2018-09-20
CA3056182A1 (en) 2018-09-20
JP2020509763A (ja) 2020-04-02
US20200056190A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
JP7177076B2 (ja) チロシン原栄養性
US12516111B2 (en) Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
EP3022304B1 (en) Methods and compositions for producing double allele knock outs
KR101114741B1 (ko) 알파-1,6-푸코실 전이효소 발현의 ｓｈｒｎａ-조절된 억제
US11549108B2 (en) Mammalian cells for producing a secreted protein
US11230725B2 (en) Cell engineering using MICRORNAs
EP3696271A2 (en) Expression cassette for production of high-expression and high-functionality target protein and use thereof
KR20100074184A (ko) 항체의 제조 방법
US20240327496A1 (en) Improved Expression Vectors and Uses Thereof
US20250304911A1 (en) Cysteine prototrophy
JP2024501662A (ja) Ｘｂｐ１を標的とするオリゴヌクレオチド
KR102956080B1 (ko) 분비형 단백질을 생산하기 위한 포유동물 세포
US20230287455A1 (en) Cells Having Gene Duplications and Uses Thereof
HK1218562B (zh) 重组多肽生产

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210226

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220629

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221026

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221110

R150 Certificate of patent or registration of utility model

Ref document number: 7177076

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150